Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression: Results From the FACE-DR Study.
J. Clin. Psychiatry. 2019-10-15; 80(6):
DOI: 10.4088/jcp.19m12755
Read on PubMed
1. J Clin Psychiatry. 2019 Oct 15;80(6):19m12755. doi: 10.4088/JCP.19m12755.
Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of
Individuals With Treatment-Resistant Depression: Results From the FACE-DR Study.
Godin O(#)(1)(2)(3), Bennabi D(#)(2)(4), Yrondi A(2)(5), Richieri R(2)(6),
D’Amato T(2)(7), Bellivier F(2)(8), Bougerol T(2)(9)(10)(11), Horn M(2)(12),
Camus V(2)(13), Courtet P(2)(14), Doumy O(2)(13), Genty JB(2)(15)(16)(17),
El-Hage W(2)(9), Haesebaert F(2)(7), Holtzmann J(2)(9)(10)(11), Lancon C(2)(6),
Leboyer M(2)(15)(16)(17), Llorca PM(2)(18), Maruani J(2)(8), Molière F(2)(10),
Samalin L(2)(18), Schmitt L(2)(5), Stephan F(2)(18), Vaiva G(2)(12), Aouizerate
MWB(2)(19), Haffen E(2)(20); FondaMental Advanced Centers of Expertise in
Resistant Depression (FACE-DR) Collaborators(2)(4).
Author information:
(1)Institut Pierre Louis d’Epidémiologie et de Santé Publique, UMR_S 1136,
Hôpital La Salpêtriere, 75651 Paris Cédex 13, France. .
(2)FondaMental Fondation, Créteil, France.
(3)INSERM, Sorbonne Université, Institut Pierre Louis d’ Épidémiologie et de
Santé Publique (IPLESP), Paris, France.
(4)Clinical Psychiatry Department, Treatment-Resistant Depression Fondamental
Expert Center, EA 481 Neurosciences, Bourgogne Franche Comté University,
Besançon, France.
(5)Psychiatry and Medical Psychology Department, Fondamental Expert Center for
Treatment-Resistant Depression, CHRU Toulouse, Purpan Hospital, Toulouse,
France.
(6)Psychiatry Department, Fondamental Expert Center for Treatment-Resistant
Depression, CHU La Conception, Marseille, France.
(7)University Hospital Department of Adult Psychiatry, Fondamental Expert Center
for Treatment-Resistant Depression, Le Vinatier Hospital, Bron, France.
(8)AP-HP, GH Saint-Louis-Lariboisière-Fernand Widal, INSERM UMRS 1144,
University Paris Diderot, Paris, France.
(9)University Joseph Fourier, Grenoble I, BP 53, Grenoble, France.
(10)CHU Grenoble, Grenoble, France.
(11)Grenoble Institut des Neurosciences (GIN) Inserm U836, Chemin Fortune
Ferrini, La Tronche, France.
(12)Department of Adult Psychiatry, Fondamental Expert Center for
Treatment-Resistant Depression, CHU Lille, CNRS UMR 9193, Lille University,
Fontan Hospital, Lille, France.
(13)University Psychiatric Clinic, Fondamental Expert Center for
Treatment-Resistant Depression, Inserm U1253 imaging and Brain:iBrain, CHRU
Tours, Tours University, Tours, France.
(14)Department of Emergency Psychiatry and Acute Care, CHU Montpellier, INSERM
U1061, Montpellier University, Montpellier, France.
(15)Paris-Est University, UMR_S955, UPEC, Créteil, France.
(16)Inserm, U955 Team 15, Créteil, France.
(17)AP-HP, H. Mondor-A. Chenevier Hospital, Psychiatry Department, Créteil,
France.
(18)CHU Clermont-Ferrand, Fondamental Expert Center for Treatment-Resistant
Depression, EA7280, Clermont-Ferrand University, Clermont-Ferrand, France.
(19)Department of General Psychiatry and Psychosocial Rehabilitation 29G01 and
29G02, Fondamental Expert Center for Treatment-Resistant Depression, CHRU Brest,
Bohars Hospital, Bohars, France.
(20)University Department of Psychiatry, Fondamental Expert Center for
Treatment-Resistant Depression, CH Charles Perrens, NutriNeuro (UMR INRA 1286),
Bordeaux University, Bordeaux, France.
(#)Contributed equally
BACKGROUND: The aim of this study was to estimate the prevalence of metabolic
syndrome (MetS) and its components in a cohort of French patients with
treatment-resistant depression (TRD) and to determine correlations with
sociodemographic, clinical, and treatment-related factors.
METHODS: From 2012 to 2018, 205 patients who met DSM-IV criteria for major
depressive episode with moderate-to-severe symptoms (Montgomery-Asberg
Depression Rating Scale score ≥ 20), and at least Stage II resistance according
to Thase and Rush criteria were enrolled in the FondaMental Advanced Centers of
Expertise in Resistant Depression (FACE-DR) cohort. Data on sociodemographic and
clinical characteristics, lifestyle information, and treatment and comorbidities
were collected, and a blood sample was drawn. MetS was defined according to the
criteria of the International Diabetes Federation.
RESULTS: Overall, 38% of individuals with TRD met criteria for MetS. The
frequency of MetS was significantly higher in men than in women only for
patients aged 40 years or older (46.3% vs 35.2%, P = .0427). Moreover, whereas
the management for diabetes was good, less than one-third of the patients with
high blood pressure or dyslipidemia were treated for these conditions.
Multivariate analysis showed that individuals with abnormal plasma c-reactive
protein levels had a 3-fold increased risk (95% CI, 1.5-5.2) of having MetS,
independent of other potential confounders.
CONCLUSION: The prevalence of MetS is higher in patients with TRD than in those
with other psychiatric disorders and characterized by a considerable
undertreatment of some components of MetS in this population. Diagnosis and
treatment of the components of MetS should be systematically performed to
prevent the occurrence of cardiovascular diseases in patients with TRD. These
findings highlight the need for integrated care, with more interaction and
coordination between psychiatrists and primary care providers.
© Copyright 2019 Physicians Postgraduate Press, Inc.
DOI: 10.4088/JCP.19m12755
PMID: 31617968 [Indexed for MEDLINE]